Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Language：English  

DOI： 10.1007/s13730-024-00890-2

Language：English   Publishing type：Research paper (international conference proceedings)  

Language：English  

Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/1744-9987.14114.

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1093/ckj/sfae021

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1007/s13730-023-00849-9.

Language：Japanese  

Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Language：English  

DOI： 10.1111/1744-9987.14046

Language：English  

DOI： 10.1007/s13730-023-00813-7

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1186/s12882-023-03190-6

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.3390/vaccines11010134.

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1186/s12992-022-00883-9.

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1038/s42003-022-03712-2.

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.3389/fmed.2022.883168

Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1038/s41598-022-10510-7

Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.3389/fmed.2022.899359.

Language：Japanese   Publisher：Pediatric Nephrology  

Background: The prevalence of magnesium imbalance in critically ill children is very high. However, its significance in the development of acute kidney injury (AKI) and mortality remains unknown. Methods: In this retrospective observational study from 2010 to 2018, the pediatric-specific intensive care database was analyzed. We included critically ill children aged > 3 months and those without chronic kidney disease. Patients were diagnosed with AKI, according to the Kidney Disease Improving Global Outcomes (KDIGO) study. We calculated the initial corrected magnesium levels (cMg) within 24 h and used a spline regression model to evaluate the cut-off values for cMg. We analyzed 28-day mortality and its association with AKI. The interaction between AKI and magnesium imbalance was evaluated. Results: The study included 3,669 children, of whom 105 died within 28 days, while 1,823 were diagnosed with AKI. The cut-off values for cMg were 0.72 and 0.94 mmol/L. Both hypermagnesemia and hypomagnesemia were associated with 28-day mortality (odds ratio [OR] = 2.99, 95% confidence interval [CI] = 1.89–4.71, p < 0.001; OR = 2.80, 95% CI = 1.60–4.89, p < 0.001). Hypermagnesemia was associated with AKI (OR = 1.52, 95% CI = 1.27–1.82, p < 0.001), while neither hypermagnesemia nor hypomagnesemia interacted with the AKI stage on the 28-day mortality. Conclusions: Abnormal magnesium levels were associated with 28-day mortality in critically ill children. AKI and hypermagnesemia had a strong association. Graphical abstract: “A higher resolution version of the Graphical abstract is available as Supplementary information”. [Figure not available: see fulltext.]

DOI： 10.1007/s00467-021-05331-1

Web of Science

Scopus

PubMed

Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1093/ckj/sfab207.

Web of Science

Authorship：Lead author,　Corresponding author  

Language：English   Publisher：Clinical and Experimental Nephrology  

Background: Pathological findings in Alport syndrome frequently show mesangial proliferation and sometimes incidental IgA deposition, in addition to unique glomerular basement membrane (GBM) changes including thin basement membrane and/or lamellation. However, similar GBM abnormalities are also often observed in IgA nephropathy. Both diseases are also known to show hematuria, proteinuria, and sometimes macrohematuria when associated with viral infection. Therefore, it can be difficult to make a differential diagnosis, even based on clinical and pathological findings. Some recent articles demonstrated that galactose-deficient IgA1 (Gd-IgA1)-specific monoclonal antibody (KM55) could potentially enable incidental IgA deposition to be distinguished from IgA nephropathy. Methods: We performed comprehensive gene screening and glomerular Gd-IgA1 and type IV collagen α5 chain immunostaining for five cases with both IgA deposition and GBM changes to confirm that Gd-IgA1 can help to distinguish these two diseases. Results: Four of the cases were genetically diagnosed with Alport syndrome (Cases 1–4) and one was IgA nephropathy with massive GBM changes, which had a negative gene test result (Case 5). In Cases 1–4, glomerular Gd-IgA1 deposition was not detected, although there was positivity for IgA in the mesangial area. In Case 5, glomerular Gd-IgA1 deposition was observed. Conclusion: Gd-IgA1 expression analysis could clearly differentiate these two disorders. This approach can be applied to identify these two diseases showing identical clinical and pathological findings.

DOI： 10.1007/s10157-021-02054-3

Scopus

PubMed

Language：Japanese   Publisher：BMC Nephrology  

Background: Patients with chronic kidney disease often experience metabolic acidosis. Whether oral sodium bicarbonate can reduce mortality in patients with metabolic acidosis has been debated for years. Hence, this study was conducted to evaluate the utility of sodium bicarbonate in patients who will undergo dialysis therapy. In this study, we investigated the effect of oral sodium bicarbonate therapy on mortality in patients with end-stage kidney disease (ESKD) initiated on dialysis therapy. Methods: We conducted an observational study of patients when they started dialysis therapy. There were 17 centres participating in the Aichi Cohort Study of Prognosis in Patients Newly Initiated into Dialysis. Data were available on patients’ sex, age, use of sodium bicarbonate, drug history, medical history, vital data, and laboratory data. We investigated whether patients on oral sodium bicarbonate for more than three months before dialysis initiation had a better prognosis than those without sodium bicarbonate therapy. The primary outcome was defined as all-cause mortality. Results: The study included 1524 patients with chronic kidney disease who initiated dialysis between October 2011 and September 2013. Among them, 1030 were men and 492 women, with a mean age of 67.5 ± 13.1 years. Of these, 677 used sodium bicarbonate and 845 did not; 13.6% of the patients in the former group and 21.2% of those in the latter group died by March 2015 (p < 0.001). Even after adjusting for various factors, the use of sodium bicarbonate independently reduced mortality (p < 0.001). Conclusions: The use of oral sodium bicarbonate at the time of dialysis initiation significantly reduced all-cause mortality in patients undergoing dialysis therapy.

DOI： 10.1186/s12882-021-02330-0

Web of Science

Scopus

PubMed

Language：English   Publishing type：Research paper (international conference proceedings)  

Publisher：BMJ Open  

DOI： 10.1136/bmjopen-2020-042315

Web of Science

Scopus

Language：Japanese   Publisher：Diagnostics  

Acute kidney injury (AKI) is a major complication of sepsis that induces acid-base imbalances. While creatinine levels are the only indicator for assessing the prognosis of AKI, prognostic importance of metabolic acidosis is unknown. We conducted a retrospective observational study by analyzing a large China-based pediatric critical care database from 2010 to 2018. Participants were critically ill children with AKI admitted to intensive care units (ICUs). The study included 1505 children admitted to ICUs with AKI, including 827 males and 678 females. The median age at ICU admission was 22 months (interquartile range 7–65). After a median follow-up of 10.87 days, 4.3% (65 patients) died. After adjusting for confounding factors, hyperlactatemia, low pH, and low bicarbonate levels were independently associated with 28-day mortality (respective odds ratio: 3.06, 2.77, 2.09; p values: <0.01, <0.01, <0.01). The infection had no interaction with the three parameters. The AKI stage negatively interacted with bicarbonate and pH but not lactate. The current study shows that among children with AKI, hyperlactatemia, low pH, and hypobicarbonatemia are associated with 28-day mortality.

DOI： 10.3390/diagnostics10110937

Web of Science

Scopus

PubMed

Language：Japanese   Publisher：一般社団法人 日本移植学会  

<p>DSAは抗体関連型拒絶反応のリスク因子であり、①CDC陽性②FCXM陽性③FCXM陰性でDSA陽性の順にDSAの力価が高いと考えられている。クロスマッチ陽性腎移植における脱感作療法後のAMR発生率は12-60％と報告されているが、DSAの力価によりAMRの発生率は異なる。今回われわれは2011年から2019年までに当院で施行された生体腎移植の77例を対象として、FCXM陽性（グループ①、26例）、FCXM陰性でDSA陽性（グループ②、3例）、FCXM陰性（グループ③、48例）に分けて拒絶反応の発生率、CMV抗原血症、生着率について検討した。輸血、妊娠、移植の感作歴はグループ①、②、③でそれぞれ53.8%、33.3%、20.8%、DSAはグループ①に3例、グループ②に3例確認された。脱感作療法としてリツキシマブはグループ①、②、③でそれぞれ65.4%、100%、35.4%に投与されていた。AMRの発生率はグループ①、②、③でそれぞれ15.4%、33.3%、2.1%であった。CMV抗原血症に対してVGCの投与を要した症例はグループ①、②、③でそれぞれ15.3%、33.3%、29.2%であった。3年生着率はグループ①、②、③でそれぞれ100%、100%、92.4%であった。FCXM陽性例およびDSA陽性例はFCXM陰性例に比較するとAMRの発生率は高いが、短期生着率に差は認めなかった。</p>

DOI： 10.11386/jst.55.Supplement_397_1

Publisher：Therapeutic Apheresis and Dialysis  

DOI： 10.1111/1744-9987.12811

Scopus

Publisher：Acta Cardiologica  

DOI： 10.1080/00015385.2018.1530085

Scopus

Publisher：PLoS ONE  

DOI： 10.1371/journal.pone.0221352

Web of Science

Scopus

Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

Publisher：Clinical and Experimental Nephrology  

Background Some studies have shown that the estimated glomerular filtration rate (eGFR) at the time of initiating dialysis was associated with mortality. However, the relationship between ratio of blood urea nitrogen to serum creatinine (BUN/Cr) and mortality is unknown. Methods The study was a multicenter, prospective cohort analysis including 1520 patients. Patients were classified into four quartiles based on the BUN/Cr ratio at the dialysis initiation, with Q1 having the lowest ratio and Q4 the highest. All-cause mortality after initiating dialysis was compared using the log-rank test. All-cause mortality of Q1, Q2, and Q3 was compared with that of Q4 using multivariate Cox proportional hazard regression analysis. Moreover, we compared the renal parameters including BUN/Cr ratio, eGFR, and creatinine clearance for sensitivity and specificity using receiver operative characteristic (ROC) curve. Results Significant differences were observed in all-cause mortality among the four groups (p<0.001). Multivariate analysis revealed that all-cause mortality was significantly higher in Q4 than in Q1 [hazard ratio (HR) = 1.82, 95% confidence interval (CI) 1.24–2.67, p = 0.002]. The increase in BUN/Cr ratio was positively associated with mortality (HR 1.04, 95% CI 1.02–1.06, p = 0.002). The sensitivity and specificity of BUN/Cr ratio for 180, 365, 730, and 1095 days mortality ranged between 0.60–0.72 and 0.59–0.71, respectively. The area under the curve of BUN/Cr for all-cause mortality was the highest among the renal parameters. Conclusion The BUN/Cr ratio at the time of initiation of dialysis was associated with all-cause mortality.

DOI： 10.1007/s10157-017-1458-x

Scopus

Language：English   Publisher：Therapeutic Apheresis and Dialysis  

Patients with malignancy have a poorer prognosis than others do, which must be taken into consideration when treating them for chronic kidney disease (CKD). However, there are few studies investigating their prognosis. This was an observational study of 515 (394 men and 121 women) stable non-dialysis patients with CKD who attended a CKD educational program. Mean age was 68.8 ± 13.0 years. Median follow-up was 968.5 days. Mean creatinine was 3.4 ± 1.6 mg/dL. Of these, 63 had malignancy and 452 did not; 20.6% of the former and 11.9% of the latter group died by the end of the study period (P = 0.0548). Malignancy was not associated with all-cause mortality (HR: 1.3475, 95% CI: 0.7202–2.5214, P = 0.3507) but with malignancy-associated mortality (HR: 3.9477, 95% CI: 1.6348–9.5331, P = 0.0023). Renal replacement therapy was not associated with mortality. Since malignancy greatly affects the prognosis, it must be taken into consideration when treating these patients.

DOI： 10.1111/1744-9987.12598

Scopus

PubMed

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publisher：Therapeutic Apheresis and Dialysis  

Patients with malignancy are reported to have poorer prognosis than those without malignancy. When patients with malignancy develop end-stage kidney disease, clinicians must determine treatment with consideration of prognosis. Furthermore, malignancy is sometimes found at time of dialysis initiation. However, prognosis of patients with malignancy at time of dialysis initiation has not been investigated. A total of 1524 patients with chronic kidney disease who initiated dialysis at 17 centers participating in the Aichi Cohort Study of Prognosis in Patients Newly Initiated into Dialysis were included. Patients initiated dialysis between October 2011 and September 2013. Mortality rates were compared between patients with and without malignancy. Types of malignancy and respective prognoses also were assessed. The study included 1030 men and 492 women with a mean age of 67.5 ± 13.1 years. Of these, 92 had malignancy and 1430 did not; 45.7% of the former group and 16.0% of the latter group died by March 2015 (P < 0.01). Even after adjusting for various factors, presence of malignancy remained an independent risk factor for mortality (P < 0.01). Patients with performance status (PS) of 0 had significantly lower mortality (P < 0.01). Patients with malignancy at time of dialysis initiation had poor prognosis. Therefore, presence of malignancy should be taken into consideration when patients initiate dialysis. In patients with malignancy, better PS was associated with better prognosis.

DOI： 10.1111/1744-9987.12525

Scopus

PubMed

Authorship：Lead author   Language：English  

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：Japanese   Publisher：Renal Replacement Therapy  

Background: The Geriatric Nutritional Risk Index (GNRI) is a nutritional screening method primarily developed for elderly people; it is also reported to be useful for predicting mortality in patients on maintenance dialysis. However, it is unclear whether it is useful at the time of dialysis initiation, which is accompanied by large weight fluctuations and unstable nutritional status. Methods: The study included 1524 patients with chronic kidney disease who commenced dialysis therapy at 17 centers. Patients commenced dialysis between October 2011 and September 2013 and were followed up until March 2015. Results: We analyzed 1489 patients whose GNRI could be calculated and whose prognosis was clear. The mean GNRI was 87.60 (median 87.86). We divided patients based on the median value into a high (H) and low (L) group. The H group included 728 patients (mean GNRI 95.2 ± 4.9, mean age 65.8 ± 13.2 years, 69.3% men), and the L group included 761 patients (mean GNRI 80.3 ± 6.1, mean age 69.1 ± 12.8 years, 66.0% men). Mortality was significantly higher in the L group (L, 22.2% vs. H, 12.6%, P < 0.001). The rates of infection-associated death in the L group was significantly higher (L, 5.5% vs. H, 1.9%, P < 0.001), although no significant difference was observed regarding cardiovascular disease-associated death (L, 7.6% vs. H, 5.2%, P = 0.059) and malignancy-associated death (L, 3.0% vs. H, 3.0%, P = 1.000). Multivariate analysis showed an association between GNRI and all-cause mortality (HR 0.9852, 95%CI 0.9707-0.9999, P = 0.049) and infection-associated death (HR 0.9484, 95%CI 0.9191-0.9786, P < 0.001). Conclusions: GNRI is useful for predicting mortality even at the time of dialysis initiation. Among the causes of death, GNRI was strongly associated with infection-associated death.

DOI： 10.1186/s41100-017-0108-9

Scopus

Language：English   Publishing type：Research paper (scientific journal)  

Language：English  

DOI： 10.1007/s10157-016-1262-z

PubMed

Authorship：Lead author   Language：English  

DOI： 10.2169/internalmedicine.56.7958

PubMed

Authorship：Lead author   Language：English  

DOI： 10.1186/s41100-017-0093-z

Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1186/s41100-016-0061-z

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1186/s41100-016-0074-7

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：English  

Language：English  

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：English  

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author  

Authorship：Lead author   Language：English  

Language：English  

Authorship：Lead author   Language：English  

Authorship：Lead author   Language：Japanese  

Authorship：Lead author   Language：Japanese  

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：Japanese  

Event date： 2023.6

Language：Japanese   Presentation type：Symposium, workshop panel (nominated)  

Venue：パシフィコ横浜  

Event date： 2023.6

Language：Japanese   Presentation type：Oral presentation (general)  

Event date： 2022.11

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：熊本城ホール  

Event date： 2022.11

Language：Japanese  

Venue：ホテル日航金沢  

Event date： 2022.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：神戸コンベンションセンター